Medical Biometrics News
-
BioIntelliSense Launches Patented, FDA-cleared Pulse Oximetry (SpO2) Sensor Technology that Addresses Skin Pigmentation and Motion Monitoring Challenges
Breakthrough pulse oximetry (SpO2 ) optical sensor solution offers medical-grade accuracy of oxygen level measurement across skin tones and while in motion Patented SpO2 sensor chipset, integrated processing and reference design capability to power the next generation of medical and consumer wearable devices BioIntelliSense, a continuous health monitoring and clinical intelligence company, ...
-
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, today announced completion and topline data from the open-label, Phase 1b clinical trial of its novel, diffusion-enhancing therapeutic, trans sodium crocetinate ...
By CervoMed
-
Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR Therapeutic Procedure in Patients with Type 2 Diabetes
REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of improvements in blood glucose, weight, and broader metabolic parameters with no device- or procedure-related adverse events in long-term follow-up after a single Revita procedure ...
-
New IVD System Enables Assay Developers and Clinical Laboratories to Accelerate Molecular Diagnostics Growth
As assay developers and clinical testing laboratories consider next steps for molecular diagnostics post-pandemic, a new in vitro diagnostic (IVD) system from Thermo Fisher Scientific will enable them to expand their assay menus and IVD testing capabilities moving forward. The Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System is a compact instrument that easily transitions from ...
-
Optimizing and Accelerating COVID-19 Predictive Modeling
The COVID-19 pandemic has wreaked havoc across the globe. As of July 30, 2021, nearly 197.5 million people have been infected with coronavirus, and 4.2 million people have died. The COVID-19 pandemic has resulted in significant pressure on healthcare systems around the globe. The need for effective diagnostic, prognostic and therapeutic procedures has never been as urgent as it is today. Despite ...
By JADBio
-
Two New Uscom Devices for China
Uscom has completed the development of two new specialised cardiovascular monitors, the “USCOM O2” and the “USCOM Basic”. The development of these two new monitors creates for Uscom a three-tier range of Uscom haemodynamic monitors for sale into China. Uscom is required to obtain regulatory approval of the China National Medical Products Administration (NMPA) for the two ...
By Uscom Ltd
-
Neurolutions Receives U.S. Food and Drug Administration De Novo Market Authorization for IpsiHand
IpsiHand robotic hand-piece uniquely leverages brain-computer interface technology for chronic stroke rehabilitation IpsiHand also has been granted U.S. FDA Breakthrough Device Designation Neurolutions, Inc., a medical device company developing and commercializing a first-of-its-kind device leveraging brain-computer interface (BCI) technology for upper extremity chronic stroke rehabilitation, ...
By Neurolutions
-
CardiacSense Medical Grade Watch receives CE Mark for continuous detection of Atrial Fibrillation
CardiacSense – a digital health company that developed and clinically verified a medical grade watch capable of detecting and remotely monitoring Atrial Fibrillation (A-Fib) and Heart Rate Variability (HRV) announced that it received the CE Mark for marketing & sales of the device in the European Union. The indications certified include “detection of Atrial Fibrillation ...
By CardiacSense
-
HealthTech Arkansas names five early-stage companies for latest cohort
HealthTech Arkansas announced the five early-stage companies selected for the 2020 HealthTech Arkansas healthcare accelerator. The accelerator is supported by 11 Arkansas healthcare organizations, including Arkansas Children’s Hospital, Arkansas Heart Hospital, Arkansas Urology, Baptist Health, CHI St. Vincent, Conway Regional Health System, Mercy, OrthoArkansas, St. Bernards Healthcare, ...
By Zeto, Inc.
-
The CardiacSense medical watch receives the Israeli Ministry of Health’s regulatory approval
This is the first medical wristwatch to receive medical regulatory approval for beat by beat heart rate monitoring and A-Fib detection with ECG accuracy The approval allows the company to start selling its medical watch to patients in Israel requiring continuous heart rate monitoring. This enables early detection of Atrial Fibrillation, which can cause severe heart problems, strokes and ...
By CardiacSense
-
CardiacSense doubles orders for its wearable medical watch with a $32.4 million contract in India
The agreement was signed with a distributor for the company’s product, which monitors detects fever, respiratory and chronic diseases as well as heart arrhythmias at a uniquely precise level of an ECG device The agreement in India brings CardiacSense’s total backlog to over $60 million. The company is in the process of receiving FDA and CE regulatory approvals for marketing in the ...
By CardiacSense
-
OXITONE, the World`s First FDA-Cleared Wrist Sensor, Pulse Oximeter Monitoring Device to Detect the Early Symptoms of COVID-19 and Other Chronic Diseases
IRVINE, Calif., May 28, 2020 (Newswire.com) - betweenMD is very excited to announce our partnership with Oxitone, makers of the world's first FDA-cleared risk monitoring device. Oxitone developed a wearable monitoring device, specifically designed and FDA-cleared for in-home use for patients with respiratory failure. This unique solution is for prolonged monitoring for those at risk for ...
-
CadiacSense unveils Its business model towards beginning of sales in 2020
The Company will enable patients to benefit from Cloud-based medical monitoring, on a monthly fee ”Towards the market entry of our medical wristwatch, the Company is launching a cloud-based service platform dedicated for end-users and their physicians, which will enable patient monitoring as part of their daily routine, in hospitals and in clinics, as well as sharing medical indices with ...
By CardiacSense
-
Ativa to validate rapid point-of-care sepsis diagnostics with Dr. James Fackler (Critical Care Medicine, Johns Hopkins
Ativa is honored to be working with Associate Professor James Fackler on developing and validating machine learning applications for critical care using digital blood samples from Ativa’s Diagnostic Workstation. Dr Fackler is a valued member of the Clinical Advisory Board and will advise Ativa on applying point of care hematology and metabolic measurement cards to provide a rapid and ...
-
Oxitone Medical has launched mass-production of new generation devices
We are excited to announce that Oxitone Medical, a world leader in wrist-wearable medical technologies, has begun mass-producing and delivering the new generation of the world’s first FDA-cleared wrist-sensor pulse oximetry monitor to our customers. In the last few months, we have been tirelessly working to release a new generation product with extended capabilities. We believe that our ...
-
Profusa Receives CE Mark Approval to Market the Wireless Lumee® Oxygen Platform for Continuous, Real-Time Monitoring of Tissue Oxygen
Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced it has received Conformité Européenne (CE) Mark approval to market its Wireless Lumee® Oxygen Platform for continuous, real-time monitoring of tissue oxygen in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from ...
-
Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of AKST4290 on Choroidal Blood Flow in Age-Related Macular Degeneration
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2 clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has treated the first patient in trial AKST4290-206 (STEEL) studying the effect of AKST4290 on choroidal blood flow (ChBF) in ...
-
Seahorse Executive Jay Teich Receives SFRBM CEO Innovator Award
Jay Teich, former Seahorse Bioscience CEO, received the first-ever CEO Innovator Award from the Society for Redox Biology and Medicine (SFRBM). This international award recognizes industry leaders who have transformed the face of scientific research in the areas of redox biology and medicine. Teich received the award in Boston on Nov. 20 during SFRBM 2015, the premier event for cutting-edge ...
-
Agilent Technologies Completes Acquisition of Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism
Agilent Technologies Inc. today announced it has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics. Agilent announced its intent to acquire Seahorse on Sept. 9. Seahorse's leading technology enables researchers to better understand cell health, function and signaling, and how the cell may be impacted ...
-
Agilent Technologies to Acquire Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism
Agilent Technologies Inc. (NYSE: A) and Seahorse Bioscience today announced they have signed a definitive agreement under which Agilent will acquire Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics. Exploration into cell metabolism is rapidly accelerating as the links between mitochondrial function and disease are increasingly ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you